"I keep getting acne even as an adult.""Just when I think it's healed, it gets red and swollen again.""I feel like it gets worse when I get busy."Acne is a chronic inflammatory skin disease medically ...

Acne vulgaris is driven by Cutibacterium acnes, sebaceous activity, and innate immune activation, leading to inflammation, scarring, and reduced quality of life. Although standard topical and systemic ...

Compared with placebo, minocycline generally improves acne, but it offers no clinical advantages over other therapies and has more serious adverse effects. (Strength of Recommendation: A, based on ...

That might not be acne? A pharmacist explains skin conditions that resemble acneYou are using acne medication, but it just ...

The acne vulgaris market is expected to progress steadily, supported by an increasing number of emerging therapies advancing through clinical development. Key players, including Ascletis Pharma and ...

Please provide your email address to receive an email when new articles are posted on . Acne vulgaris may be driven by underlying systemic, immune-inflammatory pathways. Addressing those underlying ...

Credit: Getty Images The American Academy of Dermatology has issued updated guidelines on the clinical management of acne vulgaris. The American Academy of Dermatology (AAD) has issued updated ...

Acne vulgaris and acne rosacea are two commonly seen rashes that affect the face. While the two are often confused by patients given their looks, both conditions are characteristically distinct in the ...

Acne vulgaris on the back of a healthy 13-year-old boy A dermatologist explores dealing with increasing bacterial resistance and selecting the treatment that minimizes irritation and other skin ...

Please provide your email address to receive an email when new articles are posted on . Denifanstat, a fatty acid synthase inhibitor, was effective in the treatment of moderate to severe acne vulgaris ...

Sagimet Biosciences Inc. SGMT reported 52-week data from a Phase 3 trial evaluating denifanstat for moderate to severe acne ...

Sagimet Biosciences Inc. announced positive 52-week results from the Phase 3 ASC40-304 OLE clinical trial of denifanstat in patients with moderate to severe acne vulgaris, conducted by license partner ...